RON

RON製品

All (8)
RON阻害剤 (7)
RON抗体(1)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S1561	BMS-777607	BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.	Cancer Lett, 2024, 587:216692 Nat Commun, 2023, 14(1):4162 Oncogene, 2023, 42(21):1716-1727
S1124	BMS-754807	BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.	Front Cell Neurosci, 2024, 18:1441827 Mol Neurodegener, 2023, 18(1):31 Mol Neurodegener, 2023, 18(1):31
S1361	MGCD-265 analog	MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.	Cancer Cell, 2022, S1535-6108(22)00312-9 Cell Rep Med, 2022, 3(1):100492 Protein Cell, 2019, 10(3):161-177
S2774	MK-2461	MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. Phase 1/2. .	Mol Carcinog, 2021, 60(7):481-496 G3 (Bethesda), 2021, 11(10)jkab265 Mol Cell Biochem, 2018, 449(1-2):1-8
S2201	BMS-794833	BMS-794833 is a potent ATP competitive inhibitor of Met (c-Met)/VEGFR2 with IC50 of 1.7 nM/15 nM, also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. Phase 1.	Cancer Res, 2021, canres.1428.2021
S1316	AMG-208	AMG 208 is a highly selective dual c-Met and RON inhibitor with IC50 of 9 nM for c-Met.
A2398	Narnatumab (Anti-MSPR / RON / CD136)	Narnatumab (Anti-MSPR / RON / CD136) is a fully human monoclonal antibody against RON (recepteur d'origine nantais; macrophage stimulating 1 receptor) with potential antineoplastic activity. MW: 145.5 kD.
S8676	Glumetinib	Glumetinib is a potent and highly selective c-Met inhibitor with an IC50 of 0.42 ± 0.02 nmol/L. Glumetinib has greater than 2,400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, and TyrO3.	Cell Death Dis, 2024, 15(8):600
S1561	BMS-777607	BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.	Cancer Lett, 2024, 587:216692 Nat Commun, 2023, 14(1):4162 Oncogene, 2023, 42(21):1716-1727
S1124	BMS-754807	BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.	Front Cell Neurosci, 2024, 18:1441827 Mol Neurodegener, 2023, 18(1):31 Mol Neurodegener, 2023, 18(1):31
S1361	MGCD-265 analog	MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.	Cancer Cell, 2022, S1535-6108(22)00312-9 Cell Rep Med, 2022, 3(1):100492 Protein Cell, 2019, 10(3):161-177
S2774	MK-2461	MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. Phase 1/2. .	Mol Carcinog, 2021, 60(7):481-496 G3 (Bethesda), 2021, 11(10)jkab265 Mol Cell Biochem, 2018, 449(1-2):1-8
S2201	BMS-794833	BMS-794833 is a potent ATP competitive inhibitor of Met (c-Met)/VEGFR2 with IC50 of 1.7 nM/15 nM, also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. Phase 1.	Cancer Res, 2021, canres.1428.2021
S1316	AMG-208	AMG 208 is a highly selective dual c-Met and RON inhibitor with IC50 of 9 nM for c-Met.
S8676	Glumetinib	Glumetinib is a potent and highly selective c-Met inhibitor with an IC50 of 0.42 ± 0.02 nmol/L. Glumetinib has greater than 2,400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, and TyrO3.	Cell Death Dis, 2024, 15(8):600
A2398	Narnatumab (Anti-MSPR / RON / CD136)	Narnatumab (Anti-MSPR / RON / CD136) is a fully human monoclonal antibody against RON (recepteur d'origine nantais; macrophage stimulating 1 receptor) with potential antineoplastic activity. MW: 145.5 kD.

RON阻害剤の選択性比較